CER Daily Newsfeed

Is ICER's New Digital Health Value Assessment Framework Relevant as Technology Pivots to OTC?

(9/15, Kimberly Westrich, LinkedIn) comments “...Last week, No Patient Left Behind published a white paper titled, ‘Getting the Math Right When Measuring the Value of New Medicines,’ which found that traditional cost-effectiveness analysis methods often omit sources of social value that, when incorporated, move the needle on cost-effectiveness estimates. The authors reviewed ICER assessments for 20 medications, only 8 of which were found to be cost-effective using ICER’s traditional CEA methods. However, after applying generalized cost-effectiveness analysis (GCEA) to account for 2 additional dimensions of value, including diminishing returns to health improvement and dynamic pricing, the authors found that at least 17 of the 20 assessed medications offered good value for money from a societal standpoint.” Full

Blackstone's $250M Bet Beats Xarelto in Bleeding Trial, Making Case for Anthos' Ex-Novartis Asset

(9/18, Nick Paul Taylor, Fierce Biotech) reports “...The data show Anthos Therapeutics’ abelacimab significantly cut bleeding compared to Bayer and Johnson & Johnson’s Xarelto, adding to evidence that the biotech's candidate can treat thrombosis without affecting hemostasis.” Full

EMA Waves Goodbye To HTA Network As Collaboration Framework Enters New Phase

(9/18, Eliza Slawther, Pink Sheet) reports “...A report published by the European Medicines Agency highlights milestones reached under its collaboration with EUnetHTA over recent years and outlines areas for further development once the initiative changes hands under the new HTA Regulation.” Subscription Required